文献速递糖尿病

2型糖尿病持续皮下胰岛素输注与每日多次胰岛素注射的血糖控制比较:随机对照试验的个体患者数据Meta分析与Meta回归

Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials.
PubMed 文献 · Diabetes Care · 2017-01-01

本个体患者数据Meta分析与Meta回归纳入5项随机对照试验(287例接受每日多次胰岛素注射,303例接受持续皮下胰岛素输注),比较2型糖尿病患者的血糖控制。持续皮下胰岛素输注较每日多次胰岛素注射总体HbA1c差异为-0.40%(-0.86至0.05),胰岛素剂量减少约26%,体重无差异;基线HbA1c越高、基线胰岛素剂量越大的患者获益最大。

要点

  • 持续皮下胰岛素输注较每日多次胰岛素注射总体HbA1c差异为-0.40%(-0.86至0.05)。
  • 持续皮下胰岛素输注使胰岛素剂量减少-0.25单位/kg(-0.31至-0.19),约26%降幅。
  • 基线HbA1c是最终HbA1c的最佳决定因素,基线控制越差者获益越大。

核心结论

  • 在血糖控制不佳的2型糖尿病患者中,持续皮下胰岛素输注较每日多次胰岛素注射达到更好的血糖控制,胰岛素需求量减少约26%,体重无变化。
  • 基线血糖控制最差且基线胰岛素剂量最高的患者效果最佳。

研究设计与样本

  • 个体患者数据Meta分析与Meta回归,纳入比较2型糖尿病患者持续皮下胰岛素输注与每日多次胰岛素注射期间HbA1c的随机对照试验。
  • 数据来源包括Cochrane数据库和Ovid Medline。
  • 共纳入5项试验,287例随机接受每日多次胰岛素注射,303例随机接受持续皮下胰岛素输注。
  • 采用贝叶斯Meta回归模型探索最终HbA1c水平和胰岛素剂量的患者层面决定因素,并用两步Meta分析汇总效应。
  • 低血糖数据不可用。

主要发现

  • 基线HbA1c是最终HbA1c的最佳决定因素:所有试验中HbA1c差异(%)=1.575-(0.216[95%可信区间0.371-0.043]×基线HbA1c),在随机化前优化控制的试验中效应最大。
  • 基线胰岛素剂量是最终胰岛素剂量的最佳预测因素:胰岛素剂量差异(单位/kg)=0.1245-(0.382[0.510-0.254]×基线胰岛素剂量)。
  • 总体HbA1c差异为-0.40%(-0.86至0.05[-4.4 mmol/mol(-9.4至0.6)])。
  • 总体胰岛素剂量减少-0.25单位/kg(-0.31至-0.19)(持续皮下胰岛素输注降低26%),减少-24.0单位/天(-30.6至-17.5)。
  • 两种治疗间平均体重无差异(0.08 kg[-0.33至0.48])。

局限性

  • 低血糖数据不可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare glycemic control during continuous subcutaneous insulin infusion (CSII) and multiple daily insulin injections (MDI) in people with type 2 diabetes to identify patient characteristics that determine those best treated by CSII. RESEARCH DESIGN AND METHODS: Randomized controlled trials were selected comparing HbA1c during CSII versus MDI in people with type 2 diabetes. Data sources included Cochrane database and Ovid Medline. We explored patient-level determinants of final HbA1c level and insulin dose using Bayesian meta-regression models of individual patient data and summary effects using two-step meta-analysis. Hypoglycemia data were unavailable. RESULTS: Five trials were identified, with 287 patients randomized to receive MDI and 303 to receive CSII. Baseline HbA1c was the best determinant of final HbA1c: HbA1c difference (%) = 1.575 - (0.216 [95% credible interval 0.371-0.043] × baseline HbA1c) for all trials, but with largest effect in the trial with prerandomization optimization of control. Baseline insulin dose was best predictor of final insulin dose: insulin dose difference (units/kg) = 0.1245 - (0.382 [0.510-0.254] × baseline insulin dose). Overall HbA1c difference was -0.40% (-0.86 to 0.05 [-4.4 mmol/mol (-9.4 to 0.6)]). Overall insulin dose was reduced by -0.25 units/kg (-0.31 to -0.19) (26% reduction on CSII), and by -24.0 units/day (-30.6 to -17.5). Mean weight did not differ between treatments (0.08 kg [-0.33 to 0.48]). CONCLUSIONS: CSII achieves better glycemic control than MDI in people with poorly controlled type 2 diabetes, with ∼26% reduction in insulin requirements and no weight change. The best effect is in those worst controlled and with the highest insulin dose at baseline.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pickup JC, Reznik Y, Sutton AJ, et al. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care. 2017. PMID: 28428322. doi:10.2337/dc16-2201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。